Advancing highly impactful oncology programs with best-in-class potential
Crescent’s programs are designed to optimize efficacy and safety by leveraging proven biology and mechanisms of action that have already been validated in the clinical setting. This unique approach builds on recent breakthroughs in immuno-oncology and antibody drug conjugates to create the next generation of therapies for patients with solid tumors and provides the opportunity to rapidly accelerate development timelines.
Advancing highly impactful oncology programs with best-in-class potential
Crescent’s programs are designed to optimize efficacy and safety by leveraging proven biology and mechanisms of action that have already been validated in the clinical setting. This unique approach builds on recent breakthroughs in immuno-oncology and antibody drug conjugates to create the next generation of therapies for patients with solid tumors and provides the opportunity to rapidly accelerate development timelines.
Our Pipeline
Each of our programs is designed to achieve best-in-class efficacy as a monotherapy across solid tumor indications. These programs also provide an additional unique opportunity as combinations of CR-001 with either CR-002 or CR-003 because their mechanisms of action are highly synergistic. This strategy provides the potential for broad utility across tumor types.
CR-001
CR-001, Crescent’s lead program, is a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors. It was intentionally designed to exhibit the cooperative pharmacology of ivonescimab, another tetravalent PD-1 x VEGF bispecific antibody that demonstrated efficacy superior to market-leading pembrolizumab in a large Phase 3 clinical trial. The structure of CR-001 may promote localization of the therapeutic to the tumor microenvironment to maintain the balance of efficacy and safety that defines this new class of immunotherapy.
We are focused on developing CR-001 in potential first-in-class opportunities with a rapid path to market and high probability of success based on clinical validation from approved VEGF and PD-1/PD-L1 therapies. Crescent plans to submit an IND for CR-001 in the fourth quarter of 2025 followed by a Phase 1 trial, with initial clinical data expected in the second half of 2026 in patients with solid tumors.
CR-002 & CR-003
CR-002 and CR-003 are antibody drug conjugates (ADCs) designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications. The identity of the targets of these ADCs will be disclosed as they advance, which is expected in mid-2026 for CR-002.